Figure 1
Influence of AKB-4924 treatment on disease activity in trinitrobenzene sulfonic acid (TNBS) colitis. AKB-4924 (0, 0.3, 1.0 or 5.0 mg kg−1 in cyclodextrin vehicle) was administered subcutaneously on day −1 relative to TNBS or EtOH intrarectal lavage. (a) Weight was monitored daily as an indicator of disease severity and normalized relative to initial weight and control animals. On day 7, animals were killed and colons were excised and measured to assess (b) colon length. Panel (c) represents H&E staining of (A) tissue isolated from control animals, (B) TNBS animals treated with vehicle, and (C) TNBS animal treated with AKB-4924. (d) Disease activity was assessed as sum of scoring (0–3) for colon thickening (colon weight/length), occult blood, fecal pellet consistency, and percentage of weight loss. (e) Temperature was measured by infrared (IR) thermometer at t=0, 6, 12, and 24 h and then at 24-h intervals until killing. N=6, *P<0.05, **P<0.01, ***P<0.001, #P<0.05, analysis of variance (a, e), two-tailed, Student’s t-test (b, d).
